Role of interim 18F-FDG PET/CT combined with Bcl-2/MYC protein dual expression status in risk stratification for patients with primary gastrointestinal diffuse large B-cell lymphoma / 中华核医学与分子影像杂志

ABSTRACT

Objective:To explore the potential value of interim 18F-fluorodeoxyglucose (FDG) PET/CT combined with B-cell lymphoma-2 (Bcl-2)/MYC protein dual expression (DE) status in the prognostic stratification for patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL). Methods:Forty-six patients (21 males, 25 females; age 20-83 years) with newly diagnosed PGI-DLBCL from June 2012 to May 2019 in Nanjing Drum Tower Hospital were enrolled in this retrospective study. Immunohistochemistry for Bcl-2 and MYC protein expression was performed. All patients underwent baseline and interim (after 2-4 cycles of cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP) regimen) 18F-FDG PET/CT scans for assessment. Interim 18F-FDG PET/CT results were determined based on Deauville 5-point scale (DS) and changing rate of maximum standardized uptake value (&Delta;SUV max%) in 18F-FDG PET/CT images. Kaplan-Meier survival analysis, Cox proportional hazards regression model (single factor, multiple factors analysis) were used to analyze the prognosis (3-year progression free survival (PFS) and overall survival (OS) rates). Results:Patients were followed up for 6-84 months, and 14 showed disease progression and 9 died. The PFS rate and OS rate were 69.6% and 80.4%, respectively. DE, DS as well as &Delta;SUV max% were significant predictors of PFS (hazard ratio ( HR) values 3.280, 5.120, 9.167, all P<0.05); lactate dehydrogenase (LDH), MYC protein expression, DS and &Delta;SUV max% were significant predictors of OS ( HR values 4.091, 9.618, 7.697, 11.151, all P<0.05). Multivariate analysis revealed that DS and &Delta;SUV max% were independent predictors of PFS and OS ( HR values 4.370-9.244, all P<0.05). In the DS negative (-) group, patients with DE positive (+ ) had lower PFS and OS rates than those with DE- (PFS rate 50.0% vs 88.9%; OS rate 66.7% vs 96.3%; χ2 values 6.050, 4.966, both P<0.05). In &Delta;SUV max%<90% group, patients with DE+ had lower PFS rate than those with DE- (12.5% vs 68.8%; χ2=6.649, P=0.01). Conclusions:Interim PET/CT analysis using DS and &Delta;SUV max% is able to predict survival in PGI-DLBCL patients. The combination of DS, &Delta;SUV max% and DE can risk-stratify PGI-DLBCL patient more effectively.